# Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

> **NCT06420908** · NA · WITHDRAWN · sponsor: **Hebei Medical University Fourth Hospital**

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Adebrelimab+TP/FP+ radiation therapy
- **DRUG:** Adebrelimab+FP/TP+ radiation therapy

## Key facts

- **NCT ID:** NCT06420908
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-30
- **Primary completion:** 2026-05-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The primary reason for termination was difficulty in recruitment
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06420908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06420908, "Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06420908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*